Literature DB >> 2110296

Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes.

V Barnaba1, A Franco, A Alberti, R Benvenuto, F Balsano.   

Abstract

Specific B lymphocytes can act as very efficient antigen-presenting cells. They bind antigen with high affinity via their immunoglobulin receptors, process it through the class II major histocompatibility complex (MHC) pathway, and present its fragments to class II-restricted T lymphocytes. In general, exogenous antigens and noninfectious viral particles enter the class II pathway and are selectively associated with class II MHC molecules. The presentation of an exogenous antigen in association with class I molecules has been reported for only a few antigens, including the hepatitis B envelope antigen (HBenvAg). Here we demonstrate that antigen-specific B cells can efficiently deliver HBenvAg to the class I pathway, presenting its fragments to class I-restricted cytotoxic T lymphocytes (CTLs) which kill the specific B cells. This could represent a mechanism of suppression of neutralizing anti-hepatitis B virus (HBV) antibody response, a phenomenon that accompanies the development of the chronic HBV-carrier state.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110296     DOI: 10.1038/345258a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  55 in total

1.  Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells.

Authors:  J T Voeten; G F Rimmelzwaan; N J Nieuwkoop; R A Fouchier; A D Osterhaus
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

2.  The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates.

Authors:  A Jafarzadeh; F Shokri
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

Review 3.  Immune escape by hepatitis B viruses.

Authors:  U Protzer; H Schaller
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

4.  Recipient B cells are not required for graft-versus-host disease induction.

Authors:  Catherine Matte-Martone; Xiajian Wang; Britt Anderson; Dhanpat Jain; Anthony J Demetris; Jennifer McNiff; Mark J Shlomchik; Warren D Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-23       Impact factor: 5.742

5.  Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines.

Authors:  Vijayakumar Velu; Shanmugam Saravanan; Subhadra Nandakumar; Esaki-Muthu Shankar; Appasamy Vengatesan; Suresh-Sakharam Jadhav; Prasad-Suryakant Kulkarni; Sadras-Panchatcharam Thyagarajan
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

6.  Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles.

Authors:  R Nisini; M Paroli; D Accapezzato; F Bonino; F Rosina; T Santantonio; F Sallusto; A Amoroso; M Houghton; V Barnaba
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 7.  Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view.

Authors:  S Abrignani
Journal:  Springer Semin Immunopathol       Date:  1997

8.  Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients.

Authors:  S Stoll-Becker; R Repp; D Glebe; S Schaefer; J Kreuder; M Kann; F Lampert; W H Gerlich
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

9.  Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

Authors:  R Schirmbeck; K Melber; T Mertens; J Reimann
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection.

Authors:  Yong Chen; Ram I Mahato
Journal:  J Drug Target       Date:  2008-02       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.